Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.

Détails

ID Serval
serval:BIB_03A6FCB474C2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
Périodique
Clinical cancer research
Auteur(s)
Tallón de Lara P., Cecconi V., Hiltbrunner S., Yagita H., Friess M., Bode B., Opitz I., Vrugt B., Weder W., Stolzmann P., Felley-Bosco E., Stahel R.A., Tischler V., Britschgi C., Soldini D., van den Broek M., Curioni-Fontecedro A.
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Statut éditorial
Publié
Date de publication
15/12/2018
Peer-reviewed
Oui
Volume
24
Numéro
24
Pages
6345-6354
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Combination of immune checkpoint inhibitors with chemotherapy is under investigation for cancer treatment.
We studied the rationale of such a combination for treating mesothelioma, a disease with limited treatment options.
The combination of gemcitabine and immune checkpoint inhibitors outperformed immunotherapy alone with regard to tumor control and survival in a preclinical mesothelioma model; however, the addition of dexamethasone to gemcitabine and immune checkpoint inhibitors nullified the synergistic clinical response. Furthermore, treatment with gemcitabine plus anti-PD-1 resulted in an objective clinical response in two patients with mesothelioma, who were resistant to gemcitabine or anti-PD-1 as monotherapy.
Thus, treatment of mesothelioma with a combination of gemcitabine with immune checkpoint inhibitors is feasible and results in synergistic clinical response compared with single treatment in the absence of steroids.
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/02/2019 14:53
Dernière modification de la notice
20/08/2019 12:25
Données d'usage